How to Overcome Challenges in Therapeutic Antibody Discovery

The Latest Advances in Phage Display Technology

Despite advances that include chimeric antibodies and transgenic mice, in vivo antibody production still poses many technical, financial, and ethical challenges to producing biotherapeutics. Addressing these challenges is critical, as antibodies represent an increasing fraction of therapeutics receiving FDA approval.

Read this article to learn:

• The immunogenicity, efficacy, contamination, and animal welfare issues associated with traditional in vivo antibody production approaches
• The diversity, speed, and precise control over antibody production that can be acheived with phage display
• Why other alternatives, such as transgenic mice and isolating antibodies directly from patients, are best for only very specific applications